TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
HAMPTON, N.J., Aug. 02, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2017 financial results on Tuesday, August 8, 2017 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2017 financial results and to provide an update on key research and development and business objectives for the remainder of 2017.
The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 52336196.
A replay of the call will be available approximately two hours after the live call concludes through August 15, 2017. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 52336196. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs and Administration Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director, Investor Relations & Corp Communications Celldex Therapeutics, Inc. (617) 383-3433 [email protected]
